Business

Codagenix said that it has completed a $25 million Series B extension financing, with funds primarily going to support development of its CodaVax-RSV intranasal live attenuated vaccine against respiratory syncytial virus. The FDA recently granted Fast Track designation to CodaVax-RSV. Investors in this funding round included the Serum Institute of India, Euclidean … [Read more...] about Codagenix raises $25 million for development of CodaVax-RSV intranasal vaccine against RSV

Alveolus Bio has received a 3-year Small Business Innovation Research (SBIR) FastTrack grant worth approximately $2.5 million from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) for development of an inhaled biotherapeutic for the treatment of COPD, the company said. The company's AB1000 inhaled live biotherapeutic … [Read more...] about Alveolus Bio gets $2.5 million SBIR FastTrack grant for development of inhaled live biotherapeutic

Spexis has announced a deal with SPRIM Global Investments (SGI) for funding of up to half of Spexis' costs related to Phase 3 development of ColiFin nebulized colistimethate sodium for the treatment of P. aeruginosa lung infections in patients with cystic fibrosis. Spexis was formed in December 2021 through a merger of Polyphor, which was developing inhaled … [Read more...] about Spexis gets funding for Phase 3 trials of ColiFin inhaled colistimethate sodium

Nonprofit biotech research institute Access to Advanced Health Institute (AAHI) said that it has received an award worth up to $9.9 million for a 40-month project aimed at development of liquid and dry powder versions of an intranasal influenza RNA vaccine candidate targeting the A(H5N1) and A(H7N9) avian influenza subtypes. The funding, which will support … [Read more...] about Access to Advanced Health Institute gets award worth up to $9.9 million for development of intranasal RNA flu vaccine

According to Liquidia, the US Patent Trial and Appeal Board (PTAB) has denied a request by United Therapeutics to revisit the board's July 2022 determination that none of the claims in US Patent No. 10,716,793, covering Tyvaso inhaled treprostinil, are patentable. Liquidia said that it expects United Therapeutics to appeal the denial of the rehearing to the US Court … [Read more...] about PTAB again supports Liquidia, denies United Therapeutics rehearing request for Tyvaso patent

Bharat Biotech has announced the launch of its iNCOVACC (BBV154) intranasal COVID vaccine in India for use as both primary series and booster. In September 2022, India's Central Drugs Standard Control Organization (CDSCO) approved the use of iNCOVACC in adults aged 18 and older. iNCOVACC is a recombinant replication-deficient adenovirus vectored vaccine that Bharat … [Read more...] about Bharat Biotech launches iNCOVACC intranasal COVID-19 vaccine in India